GSK and ViiV Healthcare invest £6 million in Global Fund
Pharmaceutical companies GSK and ViiV Healthcare have invested £6 million ($8 million) in the Global Fund to Fight AIDS, Tuberculosis and Malaria.
The investment will strengthen community-led responses to HIV, tuberculosis (TB) and malaria in lower income countries. The commitment will also be matched by the Gates Foundation, bringing the total investment in the Global Fund to £12 million ($16 million).
“We are proud to deepen our partnership with the Global Fund through this catalytic investment, which will help accelerate community-led responses to high burden infectious diseases such as HIV, tuberculosis, and malaria,” said Deborah Waterhouse, CEO of ViiV Healthcare and President of Global Health GSK.
“We believe that sustainable health impact begins with empowering communities and the local organisations that know them best. By supporting programmes that are led by countries, community-owned and community-driven, we’re helping to build stronger, more resilient health systems where they’re needed most.”
“The Global Fund has saved 70 million people from AIDS, TB and malaria since 2002 – but the fight isn’t over,” added Yvette Cooper, Foreign Secretary for the United Kingdom. “Climate change is contributing to a rise in malaria cases, HIV stigma still stops people from seeking treatment, and TB kills more people than any other infectious disease.”
“As the UK co-hosts the Global Fund’s 8th replenishment with South Africa, it’s really welcome and important to see British business stepping up. Private sector investment and innovation is key to finding new treatments, improving access to care and ultimately ending AIDS, TB and malaria –– because we know that global challenges won’t be solved if we wait until they land on our own doorstep.”
Investment can help drive ‘real, lasting change’
GSK and ViiV Healthcare have previously led innovation in the fight against HIV, malaria and TB, developing solutions to reduce the burden on communities most affected by highly prevalent infectious diseases. Their advances include a portfolio of medicines and vaccines which are used in the global setting for the treatment and prevention of diseases such as malaria and HIV, and a pipeline which includes research programmes for a next-generation malaria vaccine, a vaccine candidate for TB, and HIV medicines.
The funding from GSK and ViiV Healthcare will support locally led partners and programmes accelerating progress in some of the world’s most affected regions. The commitment reinforces the vital role of grassroots leadership in shaping sustainable health solutions and comes at a pivotal time in the global health response, when catalytic funding for community-owned and community-led change is more important than ever.
The announcement was made at a high-level event in London, marking a key milestone on the road to the 8th Replenishment Pledging Summit in November. The event showcased the power of partnership and solidarity to end AIDS, TB and malaria, building on recent momentum, catalysing further commitments and positioning the campaign for a successful pledging summit.
The Global Fund’s 8th Replenishment, which will finance programmes for the 2027–2029 grant cycle, is being co-hosted by the Republic of South Africa and the United Kingdom. With just five weeks to go until the Replenishment Summit, the Global Fund has raised over $3 billion, including more than $1 billion from private sector donors.
“This commitment from GSK and ViiV Healthcare sends a powerful message – when public and private actors unite around a shared vision, we can drive real, lasting change,” said Peter Sands, Executive Director of the Global Fund.
“We deeply appreciate their generosity and leadership at this critical moment. The innovation of the private sector is central to our partnership’s progress, and the renewed pledge will continue our work to ensure those most impacted by infectious diseases, including women and girls, can access the best care when they need it.”
Bruno Quinney, Content Team, DDW
